Crossmark

Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn’s disease in adults with moderate-to-severe disease

Crossref DOI link: https://doi.org/10.1186/s12955-022-01975-1

Published Online: 2022-05-07

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nag, Arpita

Romero, Beverly https://orcid.org/0000-0002-3318-119X
License Information

Text and Data Mining valid from 2022-05-07

Version of Record valid from 2022-05-07
More Information

Article History

Received: 13 August 2021

Accepted: 14 April 2022

First Online: 7 May 2022

Declarations

:

: The study was reviewed and approved by a central IRB, Salus IRB, and all procedures were in accordance with International Council on Harmonisation Good Clinical Practice, the principles of the Declaration of Helsinki, and local laws and regulations.

: All study participants consented to publication of data. All authors reviewed and approved the final manuscript and consent to its publication.

: AN, currently employed at Sanofi, was an employee of Takeda Development Center Americas at the time of the study, and holds stock in Takeda. BR is a salaried employee of ICON, which received research funds from Shire, a Takeda company for conducting the study.

Document is current

Any future updates will be listed below